GlaxoSmithKline's (GSK) drug, Augmentin, is seen in the COVID-19 Intensive Care Unit (ICU) at the Centre Cardiologique du Nord private hospital in Saint-Denis, near Paris, amid the coronavirus disease pandemic in France, May 4, 2021. REUTERS/Benoit Tessier

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

GlaxoSmithKline (GSK) sign is seen at the third China International Import Expo (CIIE) in Shanghai, China November 5, 2020. REUTERS/Aly Song

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS/Matthew Childs

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

General view outside GlaxoSmithKline (GSK) headquarters in Brentford, following the outbreak of the coronavirus disease (COVID-19), London, Britain, May 4, 2020. REUTERS/Matthew Childs

A scientist studies cancer cells inside white blood cells through a microscope at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Scientists look at test tubes containing stem cells at the GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GSK logo is seen on a flag at a GlaxoSmithKline (GSK) research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist uses a molecular weighing robot during research at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

A scientist prepares stem cells for research at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Brian McNamara, CEO of GSK Consumer Healthcare, poses for a picture at the companyÕs office in London, Britain April 4, 2019. REUTERS/Martinne Geller

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley tours GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

Scotland's First Minister Nicola Sturgeon talks with GlaxoSmithKline's (GSK’s) new CEO Emma Walmsley (L) in GSK's new production building in Montrose, Scotland, Britain October 22, 2018. Andy Buchanan/Pool via REUTERS

A general view of GlaxoSmithKline (GSK) Asia House is seen in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

A SMRT train travels past GlaxoSmithKline (GSK) Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

An aerial view of GlaxoSmithKline (GSK) Asia House is seen in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

A SMRT train travels past GlaxoSmithKline (GSK) Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

The GlaxoSmithKline (GSK) logo on top of GSK Asia House is seen through vertical louvres in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

The GlaxoSmithKline (GSK) logo is seen on top of GSK Asia House in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

An exterior view of GlaxoSmithKline (GSK) Asia House is seen in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

An aerial view of GlaxoSmithKline (GSK) Asia House is seen in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera

GlaxoSmithKline (GSK) CEO, Emma Walmsley, arrives for a meeting in Downing Street in central London, Britain, October 9, 2017. Picture taken October 9, 2017. REUTERS/Toby Melville

GlaxoSmithKline (GSK) CEO, Emma Walmsley, and Vodafone CEO Vittorio Colao, arrive for a meeting in Downing Street in central London, Britain October 9, 2017. REUTERS/Toby Melville

GlaxoSmithKline (GSK) CEO, Emma Walmsley, carries documents as she arrives for a meeting in Downing Street in central London, Britain October 9, 2017. REUTERS/Toby Melville

GlaxoSmithKline (GSK) CEO, Emma Walmsley, arrives for a meeting in Downing Street in central London, Britain October 9, 2017. REUTERS/Toby Melville

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/File Photo

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor/File Photo

A GlaxoSmithKline logo is seen outside one of its buildings in west London, February 6, 2008. REUTERS/Toby Melville/File Photo

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor/File Photo RTX11R3W GLOBAL BUSINESS WEEK AHEAD PACKAGE - SEARCH "BUSINESS WEEK AHEAD JULY 25" FOR ALL IMAGES

GlaxoSmithKline’s top-selling lung drug Advair is now facing generic competition after the drug lost patent protection.

The GlaxoSmithKline building is pictured in Hounslow, west London, Britain, June 18, 2013. REUTERS/Luke MacGregor/File Photo

Andrew Witty, CEO of GlaxoSmithKline, speaks at the Milken Institute Global Conference in Beverly Hills, California, U.S., May 2, 2016. REUTERS/Lucy Nicholson

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor/File Photo

The GlaxoSmithKline building is pictured in Hounslow, west London June 18, 2013. REUTERS/Luke MacGregor/File Photo

Signage for GlaxoSmithKline is seen on it's offices in London, Britain, March 30, 2016. REUTERS/Toby Melville/File Photo GLOBAL BUSINESS WEEK AHEAD PACKAGE - SEARCH 'BUSINESS WEEK AHEAD APRIL 25' FOR ALL IMAGES

The GlaxoSmithKline building is pictured in Hounslow, west London, Britain, in this June 18, 2013 file photo. REUTERS/Luke MacGregor/Files